ClinicalTrialsFinder
RecruitingPhase 2NCT07391241

A Phase 2 Study to Evaluate the Efficacy and Safety of Pudafensine in Vulvodynia (Provoked Vestibulodynia)

A Randomised, Double-blind, Placebo-controlled, 4-way Cross-over Trial Studying the Efficacy and Safety of Single Dose Administration of Pudafensine in Vulvodynia (Provoked Vestibulodynia).

Sponsor

Initiator Pharma

Enrollment

24 participants

Start Date

Dec 17, 2025

Study Type

INTERVENTIONAL

Conditions

Vulvodynia

Summary

The study (IP2015CS05) is a randomised, double-blind, placebo-controlled, 4-way cross-over trial studying the efficacy and safety of single dose administration of pudafensine in vulvodynia (provoked vestibulodynia) patients.

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Pudafensine for people with vulvodynia. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPudafensine

Pudafensine

Locations(1)

MAC

Blackpool, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07391241

Related Trials

Effectiveness of a Four-Session Focal Shock Wave Therapy Protocol in Women With Vulvodynia

NCT075537151 location

Biomodulation and Rehabilitation Interventions to tarGet Pelvic Health

NCT066602122 locations

Topical Ketotifen 0.25% for Secondary Vestibulodynia

NCT072570293 locations

Prospective Data Bank Creation to Study Vaginal Conditions

NCT018292041 location

Young Vulvodynia: Effect and Efficacy of Multimodal Treatment.

NCT070923321 location